vs
Side-by-side financial comparison of INVESTORS TITLE CO (ITIC) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $69.5M, roughly 1.1× INVESTORS TITLE CO). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 14.0%).
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
ITIC vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $69.5M | $75.5M |
| Net Profit | — | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 13.8% | 22.7% |
| Net Margin | — | — |
| Revenue YoY | -1.6% | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $3.97 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $69.5M | $75.5M | ||
| Q3 25 | $73.0M | $54.5M | ||
| Q2 25 | $73.6M | $52.4M | ||
| Q1 25 | $56.6M | $46.0M | ||
| Q4 24 | $70.6M | $59.1M | ||
| Q3 24 | $68.8M | $80.5M | ||
| Q2 24 | $65.4M | $47.1M | ||
| Q1 24 | $53.5M | $43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $12.2M | $8.8M | ||
| Q2 25 | $12.3M | $5.9M | ||
| Q1 25 | $3.2M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.3M | $20.3M | ||
| Q2 24 | $8.9M | $-4.5M | ||
| Q1 24 | $4.5M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 13.8% | 22.7% | ||
| Q3 25 | 20.7% | 17.6% | ||
| Q2 25 | 21.5% | 12.7% | ||
| Q1 25 | 7.2% | 8.7% | ||
| Q4 24 | 15.3% | 22.6% | ||
| Q3 24 | 16.8% | 27.4% | ||
| Q2 24 | 17.2% | -4.6% | ||
| Q1 24 | 10.8% | -5.3% |
| Q4 25 | — | — | ||
| Q3 25 | 16.7% | 16.2% | ||
| Q2 25 | 16.7% | 11.2% | ||
| Q1 25 | 5.6% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.5% | 25.2% | ||
| Q2 24 | 13.6% | -9.6% | ||
| Q1 24 | 8.5% | -11.0% |
| Q4 25 | $3.97 | $0.26 | ||
| Q3 25 | $6.45 | $0.17 | ||
| Q2 25 | $6.48 | $0.12 | ||
| Q1 25 | $1.67 | $0.06 | ||
| Q4 24 | $4.41 | $0.40 | ||
| Q3 24 | $4.92 | $0.41 | ||
| Q2 24 | $4.70 | $-0.09 | ||
| Q1 24 | $2.40 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.6M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $268.3M | $130.3M |
| Total Assets | $363.1M | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.6M | $97.5M | ||
| Q3 25 | $110.8M | $94.4M | ||
| Q2 25 | $90.1M | $96.0M | ||
| Q1 25 | $81.7M | $93.2M | ||
| Q4 24 | $83.8M | $101.0M | ||
| Q3 24 | $112.9M | $96.7M | ||
| Q2 24 | $111.2M | $96.8M | ||
| Q1 24 | $135.0M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $268.3M | $130.3M | ||
| Q3 25 | $278.0M | $115.3M | ||
| Q2 25 | $266.2M | $104.7M | ||
| Q1 25 | $254.4M | $97.1M | ||
| Q4 24 | $251.8M | $92.1M | ||
| Q3 24 | $271.3M | $71.1M | ||
| Q2 24 | $261.8M | $48.5M | ||
| Q1 24 | $254.0M | $51.0M |
| Q4 25 | $363.1M | $216.3M | ||
| Q3 25 | $363.3M | $202.9M | ||
| Q2 25 | $345.8M | $194.9M | ||
| Q1 25 | $333.8M | $196.2M | ||
| Q4 24 | $333.6M | $213.3M | ||
| Q3 24 | $352.0M | $220.7M | ||
| Q2 24 | $340.3M | $205.0M | ||
| Q1 24 | $329.5M | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.9M | $14.4M |
| Free Cash FlowOCF − Capex | $25.4M | $14.4M |
| FCF MarginFCF / Revenue | 36.5% | 19.1% |
| Capex IntensityCapex / Revenue | 8.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $47.1M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.9M | $14.4M | ||
| Q3 25 | $17.2M | $9.7M | ||
| Q2 25 | $8.9M | $14.1M | ||
| Q1 25 | $-75.0K | $3.6M | ||
| Q4 24 | $29.8M | $15.6M | ||
| Q3 24 | $7.8M | $11.0M | ||
| Q2 24 | $8.4M | $1.0M | ||
| Q1 24 | $1.4M | $11.2M |
| Q4 25 | $25.4M | $14.4M | ||
| Q3 25 | $15.8M | $9.7M | ||
| Q2 25 | $7.3M | $14.1M | ||
| Q1 25 | $-1.4M | $3.6M | ||
| Q4 24 | $22.4M | $15.6M | ||
| Q3 24 | $6.1M | $11.0M | ||
| Q2 24 | $6.3M | $1.0M | ||
| Q1 24 | $-793.0K | — |
| Q4 25 | 36.5% | 19.1% | ||
| Q3 25 | 21.7% | 17.7% | ||
| Q2 25 | 9.9% | 26.8% | ||
| Q1 25 | -2.5% | 7.7% | ||
| Q4 24 | 31.7% | 26.4% | ||
| Q3 24 | 8.8% | 13.7% | ||
| Q2 24 | 9.7% | 2.1% | ||
| Q1 24 | -1.5% | — |
| Q4 25 | 8.0% | 0.0% | ||
| Q3 25 | 1.8% | 0.0% | ||
| Q2 25 | 2.1% | 0.0% | ||
| Q1 25 | 2.4% | 0.1% | ||
| Q4 24 | 10.5% | 0.0% | ||
| Q3 24 | 2.5% | 0.0% | ||
| Q2 24 | 3.2% | 0.0% | ||
| Q1 24 | 4.2% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.40× | 1.10× | ||
| Q2 25 | 0.72× | 2.41× | ||
| Q1 25 | -0.02× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.84× | 0.54× | ||
| Q2 24 | 0.95× | — | ||
| Q1 24 | 0.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
